A new application of DNA testing, already used in a number ofworkers' health injury cases, has the potential to save insurersbillions of dollars in defense costs, a scientist who pioneered theprocess said.
Dr. Bruce S. Gillis, chief executive officer of the CytokineInstitute in Los Angeles, said the trademarked technology--called"msds1" (otherwise known as Cytokine testing)--can ascertain if aperson has had an injurious exposure to virtually any chemical ortoxin and whether they experience pain from an injury.
The process has already been applied to two dozen workers'compensation cases in California, resulting in one settlement thatthe defense attorney on the case says has easily saved the insurerinvolved $1 million.
Continue Reading for Free
Register and gain access to:
- Breaking insurance news and analysis, on-site and via our newsletters and custom alerts
- Weekly Insurance Speak podcast featuring exclusive interviews with industry leaders
- Educational webcasts, white papers, and ebooks from industry thought leaders
- Critical converage of the employee benefits and financial advisory markets on our other ALM sites, BenefitsPRO and ThinkAdvisor
Already have an account? Sign In Now
© 2024 ALM Global, LLC, All Rights Reserved. Request academic re-use from www.copyright.com. All other uses, submit a request to [email protected]. For more information visit Asset & Logo Licensing.
